Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongluo Shumu Decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically investigated for the treatment of aqueous-deficient dry eye disease (ADDE). The therapeutic rationale is based on the TCM principles of 'Tongluo' (unblocking the collaterals or meridians) and 'Shumu' (soothing or dredging the 'wood' element, which corresponds to the Liver in TCM theory). The decoction is intended to address the underlying pathophysiology of tear deficiency by promoting the flow of Qi and blood to the eyes and resolving collateral obstruction. It is typically administered as an oral liquid preparation and has been evaluated in exploratory clinical trials to assess its efficacy in improving tear film stability and secretion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongluo Shumu Decoction.